The pharmacological consequences of the binding of anti-rheumatic drugs to plasma proteins in the treatment of rheumatoid arthritis.
Evidence is presented that rheumatoid arthritis is a disease resulting from abnormal protein binding and that anti-rheumatic drugs act by correcting the abnormal binding.